## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Scoping**

## STA Phentermine with topiramate for the treatment of obesity and overweight

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Issue 1: The specification of appropriate BMI ranges should take into account the relevance of ethnicity in relation to risk profile.

This issue was raised in a consultation comment and discussed at the scoping workshop. The manufacturer stated that specific BMI ranges are likely to be included in the marketing authorisation, however these BMI cut off values are unknown at present.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The Committee may need to consider the need for different BMI ranges for people from certain ethnic backgrounds in line with current NICE guidance documents (TA203 and CG87) for type 2 diabetes (which have included lower BMI ranges for people from certain ethnic backgrounds, including people of South Asian family origin).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of phentermine with

topiramate for the treatment of obesity and overweight

Issue date: September 2012

The background section of the scope has been amended to include further information on BMI ranges for people from certain family origins, in line with recommendations in TA203 and CG87. The 'Other Considerations' section of the scope has also been amended to state 'The need for different BMI ranges for people from certain ethic backgrounds will be considered'.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to the equality issue have been identified.

Approved by Associate Director: Helen Knight

Date: 14/09/2012